(February 27, 2018, 12:47 PM EST) -- WASHINGTON, D.C. — A drugmaker cannot shield its patents from federal review by using an Indian tribe’s sovereign immunity, the U.S. Patent Trial and Appeal Board held Feb. 23 (Mylan Pharmaceuticals Inc., et al. v. Saint Regis Mohawk Tribe, Nos. IPR2016-01127, IPR2016-01128, IPR2016-01129, IPR2016-01130, IPR2016-01131 and IPR2016-01132, U.S. PTAB)....